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Purpose: This study was designed to evaluate the dosimetric feasibility of definitive stereotactic body radiation
therapy (SBRT) for the treatment of medically inoperable early stage endometrial cancer.
Methods: CT simulation scans from 10 medically inoperable early stage endometrial cancer patients previously
treated with high dose-rate (HDR) intracavitary brachytherapy were used to generate Helical Tomotherapy (HT)
plans using the IMRT mode with clinical target volumes (CTVs) that included the uterus plus cervix. A prescription
dose of 34 Gy in 4 fractions was used. The SBRT dosimetry was compared to the 10 prior intracavitary brachytherapy
plans normalized to a standard dose. Organs at risk (OARs) evaluated were the bladder, rectum, sigmoid, femoral heads,
and other bowel, including both large and small bowel. The simulation CT and daily image guidance for 4 patients
treated with this technique were evaluated to assess for interfraction variation in the uterine position and effects on
dosimetry.
Results: Compared to intracavitary brachytherapy, HT SBRT produced significantly greater overall target coverage to
the uterus, boost CTV, and PTV, with exception of the V150% of the uterus. HT SBRT significantly increased dose to the
rectum, bowel, and femoral heads compared to intracavitary brachytherapy, though not outside of dose tolerance
limits. Review of daily image guidance for patients treated with this technique demonstrated good reproducibility with
a mean overlap index of 0.87 (range, 0.74 – 0.99).
Conclusions: Definitive SBRT for medically inoperable early stage endometrial cancer appears to be a feasible
treatment option. Future studies are warranted to evaluate long-term clinical outcomes with this technique,
compared to HDR intracavitary brachytherapy.
Keywords: SBRT, Medically inoperable, Endometrial cancer, Intracavitary brachytherapyBackground
The American Cancer Society estimates that 49,560 new
cases of endometrial cancer will be diagnosed in the
United States in 2013 [1]. Nearly 70% of all endometrial
cancers in the United States are early stage at disease pres-
entation [2], equating to a predicted 33,701 diagnoses of
early stage endometrial cancer in the United States in
2013. Optimally, early stage endometrial cancer is staged
and treated with surgery, including a hysterectomy and* Correspondence: tns3b@virginia.edu
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unless otherwise stated.bilateral salpingo-oophorectomy, with or without lym-
phadenectomy, and then appropriate adjuvant therapy
may be considered [3]. Unfortunately, some patients are
ineligible for surgery because of medical conditions such
as morbid obesity or cardiopulmonary dysfunction that
make surgical or anesthesia too risky [4].
Medically inoperable early stage endometrial cancer is
routinely treated with intracavitary brachytherapy using
a device such as a Y-applicator or Heyman’s capsules, either
alone or in combination with pelvic external beam radiation
therapy [5]. Placement of the intracavitary applicators
may require the use of general or regional anesthesia intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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medical contraindications to surgery, such as morbid
obesity, advanced age and cardiopulmonary disease, may
similarly increase the risks from anesthesia and brachy-
therapy [6-8]. Published reports suggest that brachyther-
apy can be delivered safely and effectively for medically
inoperable endometrial cancer [4,9], however this
patient population is considered at high risk from
procedures and anesthesia by virtue of classification as
medically inoperable. Nguyen and Petereit reported out-
comes of 36 women with medically inoperable endometrial
cancer who received high-dose-rate (HDR) brachytherapy
at a single institution; they observed a 21% rate of late
complications and 2 patients died from acute cardiovascu-
lar events within 30 days of treatment [10]. At our institu-
tion, due to the invasiveness of the procedure and/or risks
of anesthesia, it is not uncommon for these patients or
their families to refuse brachytherapy or for patients to be
considered ineligible for anesthesia.
An external beam radiation therapy (EBRT)-only stra-
tegy for the definitive treatment of early stage medically
inoperable endometrial cancer could offer some advan-
tages for these patients since EBRT would avoid the risk
of anesthesia, applicator placement and immobilization.
However, EBRT has some general limitations for such
treatment and the physical characteristics of EBRT are
inherently inferior to brachytherapy. Without brachyther-
apy, EBRT alone suffers from inability to generate com-
paratively high doses to tumors otherwise accessible by
brachytherapy, thus there is a theoretical risk of decreased
local tumor control. Additionally, studies of interfraction
uterine positioning during definitive RT for cervical cancer
[11,12] raise concerns regarding day-to-day motion that
theoretically may further complicate the local tumor
control and normal tissue toxicity from EBRT for medic-
ally inoperable endometrial cancer. Brachytherapy avoids
concern, since it is placed directly within the uterus target
volume.
For patients at highest risk of complications from anesthesia
and brachytherapy, stereotactic body radiation therapy
(SBRT) may allow for the reproducible delivery of high
doses of radiation to the uterus and providing a back-up
alternative for select patients. Kemmerer et al. explored
the utility of EBRT with an SBRT boost for medically in-
operable endometrial cancer and found the option to
be safe and effective for the early stage patients in their
cohort [13]. In the current study, we further develop the
concept of SBRT for medically inoperable early stage endo-
metrial cancer with the aim of providing a potential alter-
native to brachytherapy when it is considered medically
necessary to avoid the risks of anesthesia, immobilization,
and applicator placement.
Here, we report a dosimetric evaluative study that com-
pares a proposed SBRTapproach using Helical Tomotherapy(Accuray Inc., Sunnyvale, CA) to high-dose-rate (HDR)
intracavitary brachytherapy for medically inoperable,
(FIGO) Stage I-II endometrial cancer patients. In addition,
we identify appropriate dose-volume parameters for the
SBRT strategy and evaluate the interfraction motion
observed among 4 consecutive patients treated at our
institution who were treated with EBRT.
Methods
Subjects
With institutional review board approval, we identified
10 patients who received HDR intracavitary brachythe-
rapy at our institution for medically inoperable, FIGO
Stage I-II endometrial cancer in order to perform a dosi-
metric analysis of SBRT versus HDR brachytherapy. Among
these 10 subjects, the contributing comorbidities to medi-
cally inoperable status included: morbid obesity (n = 6),
cardiovascular dysfunction (n = 6), severe anemia (n = 1)
and end-stage cirrhosis (n = 1). A Y-shaped applicator
(two tandems) was used for 3 patients, while a single
tandem was used for 7 patients. The Y-applicators were
placed under general anesthesia, and the single tandems
were placed under mild sedation. There were no cases
where Heyman’s capsules were used, since this approach
is not used at our institution. Five patients received HDR
brachytherapy alone, and 5 patients received brachythe-
rapy combined with pelvic EBRT. Perioperative complica-
tions included severe pain (n = 3), uterine perforation (n = 1),
and decreased oxygen saturation (n = 2). Interfraction
variation in uterine position was studied using treatment
planning and daily image guidance scans for a separate
group of 4 patients who received EBRT for medically
inoperable uterine cancer at our institution.
Treatment planning
In order to permit dosimetric comparison of the HDR in-
tracavitary brachytherapy to the proposed SBRT approach,
the brachytherapy plans for each patient were copied and
rescaled in the BrachyVision® (Varian Medical Systems,
Palo Alto, CA) treatment planning system (TPS) to reflect
a standardized prescription of 34 Gy in 4 fractions to
the clinical target volume (CTV), defined as the uterus
plus the cervix. This dose is consistent with American
Brachytherapy Society guidelines for HDR brachytherapy
monotherapy for inoperable endometrial cancer [5]. The
CT scan from brachytherapy included the applicator as
placed by the physician for brachytherapy, with the intent
of representing actual, rather than ideal, coverage. The
target volume coverage by the prescription dose is antici-
pated to vary with quality of applicator placement, and
to be lower for single tandem than for Y-applicator plans.
Treatment planning involved three-dimensional planning,
which has been shown to reduce doses to normal tissue
structures in this setting [14]. All CT images were obtained
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with 2–3 mm slice thickness. The remaining contoured
volumes included the following organs-at-risk (OARs):
bladder, rectum, sigmoid colon, other bowel (all individual
loops of large and small bowel within 1 jaw width of the
uterus), and bilateral femoral heads.
The same 10 CT scans and all contours were trans-
ferred from the BrachyVision® TPS to the Tomotherapy
TPS. SBRT planning was conducted on the Tomother-
apy TPS using the following parameters: intensity modu-
lated radiation therapy (IMRT) mode, 2.5 cm jaw width,
pitch of 0.287, and modulation factor of 2.5. The CTV
was again defined as the uterus plus the cervix and was
set as the prescription structure, while a 1 cm uniform
volumetric contraction of the uterus was used to gene-
rate a boost CTV. The 1 cm contraction was chosen em-
pirically as an approximation of the endometrial surface.
A planning target volume (PTV) was generated based
upon a 2 mm symmetric expansion of the primary CTV
(uterus plus cervix). Target dose prescriptions for the
SBRT treatments included the following: a minimum of
90% of the CTV to receive 34 Gy in 4 fractions (equivalent
dose in 2-Gy fractions (EQD2) of 52.4 Gy), a minimum of
90% of a Boost CTV to receive 48 Gy in 4 fractions
(EQD2 of 88.0 Gy), and a minimum of 90% of an expan-
sion PTV to receive 21 Gy in 4 fractions (EQD2 of 26.7
Gy). The dose fractionation for SBRT and use of a Boost
CTV structure was chosen to simulate standard HDR
brachytherapy dose distributions delivered as monothe-
rapy for medically inoperable endometrial cancer [5].
Dosimetric endpoints evaluated
As mentioned, the following OARs were contoured for
both brachytherapy and SBRT plans: bladder, rectum, sig-
moid colon, other bowel (all individual loops of large and
small bowel within 1 jaw width of the uterus), and bilateral
femoral heads. Contouring and dose restriction of the
bowel was necessary to yield bowel doses inside of tole-
rance limits for the SBRT plans. Normal tissue dose tole-
rance limits were set using recommendations from the
American Association of Physicists in Medicine (AAPM)
Group 101, a pelvic SBRT RTOG trial, (0938) and guide-
lines from the American Brachytherapy Society (ABS) and
the gynecological working group of GEC-ESTRO (Groupe
Européen de Curiethérapie and European Society for
Radiotherapy & Oncology) (see Table 1) [15-18]. When
needed, the biological effective dose (BED) of these limits
were calculated and converted to the 4-fraction treatment
equivalent. BED was calculated by
BED ¼ nd 1þ d
α=β
 
where d is the fractional dose and n is the number of
fractions. The limit BEDs were calculated using an alpha-beta ratio (α/β) of 10, traditionally viewed as the α/β of
acute effects. In addition to those data points, traditio-
nally important parameters in brachytherapy and SBRT
were also included. The final list of examined dosimetric
parameters included: highest dose encompassing 90%
(D90%) of the Boost CTV; D90% of PTV; uterus volume
(uterus plus cervix) D95%, D90%, D50%, and volume
receiving 150% of the prescription dose (V150%); the dose
received by the hottest 0.1 cc (D0.1 cc), 1 cc (D1 cc), and
2 cc (D2 cc) for the bladder, rectum and sigmoid, and ad-
ditional dose-volume points shown in Table 2. Dosimetric
statistics for the brachytherapy plans were extracted di-
rectly from the BrachyVision® software. The dose-volume
histograms for the SBRT plans were first converted into
text file (.txt) format and then analyzed using 2011 Excel
software (Microsoft, Redmond, WA) in order to obtain
the data point values. After confirming that the data were
normal distributed, statistical comparisons between SBRT
and brachytherapy plans were performed using two-tailed
T test with threshold for significance of p < 0.05.
Interfraction variation in uterine position
Evaluation of interfraction variation of the uterus for 4
consecutive medically inoperable endometrial cancer
patients treated with EBRT alone at our institution was
performed by comparing uterine position on the simula-
tion CT to daily imaging from the treatment machine.
Patients were simulated in the supine position and were
immobilized using the BodyFix system. Patients were
instructed to empty their bladder prior to simulation and
prior to each fraction of radiation therapy. No specific
bowel preparatory instructions were given. Prior to each
treatment on the Tomotherapy HD unit, an MVCT was
obtained which included the entire uterus and shifts were
made to optimize soft tissue alignment. Each pre-treatment
MVCT image was co-registered to the respective treatment
planning CT in Velocity (Velocity Medical Solutions,
Atlanta, GA) using the shifts applied on the treatment
machine. The CTV uterus was contoured on each
MVCT for comparison to the simulation CT. Two metrics
were used assess for interfraction reproducibility of the
uterine position: (1) overlap index and (2) daily D90 of the
CTV uterus. The overlap index was defined as: (volume of
CTV uterus on the MVCT overlapping with the CTV
uterus from the treatment planning CT)/(volume of CTV
uterus from the treatment planning CT). The daily D90
for the CTV uterus was obtained from dose volume histo-
gram data in Velocity after co-registration of the daily
MVCT with the treatment planning CT.
Results
We offer the computations in Table 1 as future reference for
normal dose limits for 4-fraction pelvic SBRT treatments.









(α/β = 10)Volume Threshold dose (Gy) per fx
Bladder
<1 cc 8.93 1 cc RTOG 0938 <105% Rx 67 67.6
<2 cc 4.60 2 cc Institutional* 4.8 Gy × 4 – –
<15 cc 4.50 15 cc TG-101 5.6 Gy × 3 26.2 26.1
90% 7.65 D10% RTOG 0938 <90% Rx 53.9 54.0
50% 4.25 D50% RTOG 0938 <50% Rx 24.7 24.2
Rectum
<1 cc 8.93 1 cc RTOG 0938 <105% Rx 67 67.6
<2 cc 4.60 2 cc Institutional* 4.8 Gy × 4 – –
<3 cc 8.08 3 cc RTOG 0938 <95% Rx 58.1 58.4
<20 cc 6.50 20 cc TG-101 8 Gy × 3 43.2 42.9
90% 7.65 D10% RTOG 0938 <90% Rx 53.9 54.0
80% 6.80 D20% RTOG 0938 <80% Rx 45.8 45.7
50% 4.25 D50% RTOG 0938 <50% Rx 24.7 24.2
Sigmoid colon
<2 cc 4.80 2 cc Institutional* 4.8 Gy × 4 – –
<20 cc 6.50 20 cc TG-101 8 Gy × 3 43.2 42.9
Other bowel
Small bowel <5 cc 4.75 5 cc TG-101 5.9 Gy × 3 28.1 28.0
Large bowel <20 cc 6.50 20 cc TG-101 8 Gy × 3 43.2 42.9
Femoral Heads
Point 6.89 Max RTOG 0938 <81% Rx 46.6 46.5
<10 cc 4.59 10 cc RTOG 0938 <54% Rx 27.2 26.8
These are proposed guidelines that were used as constraints in the current study. References for each parameter are listed.
*In accordance with our institutional per-fraction brachytherapy policy.
Abbreviations: SBRT stereotactic body radiation therapy, fx fraction, BED biological effective dose, Rx prescription dose, D(x)% dose to x percent of the volume,
RTOG Radiation Therapy Oncology Group, TG-101 stereotactic body radiation therapy Task Group 101.
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normal tissue dose-volume constraints for all ten patients
evaluated (Table 2). However, the D5 cc goal for small
bowel was exceeded in Tomotherapy plans for 8 of 10 pa-
tients. The target dose limit for D5 cc of small bowel was
4.75 Gy per fraction, and the 10 HT SBRT plans yielded
an average D5 cc of 5.03 ± 0.46 Gy. There were 6 patients
whose HDR brachytherapy plans did not meet specified
bladder 2 cc goals. For 4 of these 6 cases, the SBRT plans
also did not meet bladder 2 cc goals; however, SBRT plans
achieved bladder goals in 2 of these 6 patients. The overall
average bladder 2 cc goals were met for both HDR brachy-
therapy and SBRT. Rectum 2 cc constraints were exceeded
in 1 HDR brachytherapy plan, and the SBRT plan for that
patient was able to meet that goal. Sigmoid 2 cc con-
straints were exceeded in 5 HDR brachytherapy plans and
3 SBRT plans. The overall average sigmoid 2 cc goals were
met for both HDR brachytherapy and SBRT. A represen-
tative comparison of HDR brachytherapy and SBRT plans
is shown in Figure 1, which depicts a mid-sagittal imagefrom the treatment plans for a single patient evaluated in
this study.
The average and standard deviation values for each
dose-volume parameter for HDR brachytherapy plans
and Tomotherapy SBRT plans are displayed in Tables 2
and 3, along with p value for statistical comparisons be-
tween SBRT and brachytherapy plans. In general, SBRT
treatment planning achieved higher percentage of target
volume coverage than brachytherapy (Table 3). For ex-
ample, the average D95% for the uterus was over 350%
higher for SBRT compared to brachytherapy (8.34 ± 0.05
Gy per fraction versus 2.34 ± 1.26 Gy, respectively; p <
0.001). However, brachytherapy plans were associated
with higher average V150% for the uterus (22.7%) than
SBRT plans (16.7%) (p = 0.025).
Interfraction variation in uterine position
Pre-treatment MVCT imaging was reviewed for 4 pa-
tients, for 4 fractions each, for a total of 16 MVCT scans.
For the entire cohort, the mean overlap index was 0.87




Mean dose (Gy, per fx) ± SD
p-valueI-BT SBRT
Bladder
D50% 4.25 2.04 ± 0.78 1.76 ± 1.08 NS
D10% 7.65 3.73 ± 1.44 3.65 ± 1.37 NS
D0.1 cc - 6.44 ± 3.05 5.55 ± 1.46 NS
D1 cc 8.93 5.22 ± 2.27 4.76 ± 1.48 NS
D2 cc 4.60 4.68 ± 2.02 4.34 ± 1.51 NS
Rectum
D50% 4.25 0.83 ± 0.37 1.20 ± 0.63 NS
D20% 6.80 1.27 ± 0.85 2.25 ± 0.76 NS
D10% 7.65 1.56 ± 1.21 2.65 ± 0.75 NS
D0.1 cc - 2.64 ± 2.68 4.25 ± 1.25 NS
D1 cc 8.93 2.14 ± 1.98 3.37 ± 0.80 NS
D2 cc 4.60 1.91 ± 1.65 3.07 ± 0.74 NS
D20 cc 6.50 0.93 ± 0.50 1.40 ± 0.84 NS
Sigmoid
D0.1 cc - 5.41 ± 1.66 5.77 ± 0.52 NS
D2 cc 4.80 4.05 ± 1.18 4.48 ± 0.49 NS
D20 cc 6.50 1.73 ± 0.82 2.65 ± 0.78 0.02
Other bowel
D0.1 cc - 3.49 ± 1.43 6.69 ± 0.55 <0.005
D2 cc - 2.66 ± 1.11 5.56 ± 0.45 <0.005
D5 cc 4.75 2.28 ± 0.99 5.03 ± 0.46 <0.005
D20 cc 6.50 1.51 ± 0.64 3.94 ± 0.62 <0.005
Femoral Heads
Max 6.89 0.83 ± 0.22 2.83 ± 1.22 <0.005
D10 cc 4.59 0.57 ± 0.15 2.22 ± 1.09 <0.005
Abbreviations: SD standard deviation, I-BT intracavitary brachytherapy, SBRT stereotactic body radiation therapy, fx fraction, V(x)% the percentage volume of the
structure receiving x percent of the prescription dose of 8.5Gy, D(x)% the highest dose received by x percent of the volume, NS non-significant.
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D90 for coverage of CTV uterus was 99.4% of the pre-
scription dose (range, 84.2 – 110.0%). Data are summa-
rized in Table 4.
Discussion
In this study, we compared dosimetric parameters ob-
served with Helical Tomotherapy SBRT to those of in-
tracavitary brachytherapy for the definitive treatment of
medically inoperable early stage endometrial cancer. In
all 10 cases, the SBRT achieved higher percentage overall
dosimetric coverage of the uterus, Boost CTV, and PTV,
as demonstrated by the D90%. However, intracavitary
brachytherapy plans yielded a greater volume of the
uterus receiving 150% of the prescription dose, which
suggests that brachytherapy would achieve higher likeli-
hood of tumor control at a given prescription dose.
Since the brachytherapy cases included the some single-tandem applications, which result in inferior coverage
compared to Y-applicators, the observed coverage diffe-
rence between SBRT and brachytherapy may be overesti-
mated in this study. The SBRT plans achieved most
normal tissue dose constraints, but HT SBRT was asso-
ciated with increased doses to the sigmoid colon, bowel
and femoral heads compared to brachytherapy. Given
the lack of data on clinical outcomes, the reduced
V150% for the CTV and the higher doses to the bowel
suggest that SBRT warrants further study before being
implemented in the clinic. Review of daily image guid-
ance scans for a cohort of 4 patients who received EBRT
for medically inoperable endometrial cancer at our insti-
tution suggests that there is good reproducibility of ute-
rine target volume positioning and dosimetry between
fractions. However, the number of patients evaluated in
this study is small, and concerns remain regarding inter-
fraction uterine motion. Based on observations in the
Figure 1 Sagittal images from treatment plans for HDR brachytherapy (A) and Tomotherapy SBRT (B) approaches for a single patient
with medically inoperable endometrial cancer. Both treatment plans were performed with goal of delivering 8.5 Gy per fraction to the uterus.
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alternative to intracavitary brachytherapy for those me-
dically inoperable endometrial cancer patients who are
at high risk of procedural or anesthesia-related compli-
cations, but this study also highlights the superiority of
brachytherapy with respect to delivering very high doses
to tumors (e.g., V150%) and reducing dose to OARs
(e.g., bowel).Although the current study evaluates dosimetric cha-
racteristics of HT SBRT plans, relative to brachytherapy,
conclusions are limited by the lack of evidence regarding
tumor control and toxicity outcomes with this treatment.
In this study, definitive SBRT produced increased overall
dose to the target volume compared to brachytherapy,
while lowering the V150% of the target. Theoretically, the
significant volume of tumor exposed to higher doses
Table 3 Target volume dosimetric comparison of
stereotactic body radiation therapy and intracavitary
brachytherapy
Site Volume
Mean dose (per fx) ± SD
p-valueI-BT SBRT
Uterus
V150% 22.66 ± 7.21 16.66 ± 5.44 0.05
D95% (Gy) 2.34 ± 1.26 8.34 ± 0.05 <0.005
D90% (Gy) 2.76 ± 1.44 8.69 ± 0.09 <0.005
D50% (Gy) 6.06 ± 2.88 10.48 ± 0.31 <0.005
BoostCTV
D90% (Gy) 5.62 ± 3.79 12.10 ± 0.45 <0.005
PTV
D90% (Gy) 2.48 ± 1.27 7.98 ± 0.25 <0.005
Abbreviations: SD standard deviation, I-BT intracavitary brachytherapy, SBRT
stereotactic body radiation therapy, fx fraction, V150% the percentage volume
of the structure receiving 150 percent of the prescription dose of 8.5 Gy, D(x)%
the highest dose received by x percent of the volume.
Table 4 Summary of calculated D90 (as percentage of
prescription dose) and overlap index for 4 patients who
received external beam radiation therapy for medically
inoperable endometrial cancer
Patient 1 D90 (% prescription dose) Overlap index
CTV uterus 110.2
Fraction 1 110.0 0.86
Fraction 2 97.4 0.74
Fraction 3 105.7 0.89
Fraction 4 101.1 0.83
Patient 2 D90 (% prescription dose) Overlap index
CTV uterus 100.7
Fraction 1 100.6 0.92
Fraction 2 100.6 0.93
Fraction 3 100.5 0.89
Fraction 4 96.4 0.80
Patient 3 D90 (% prescription dose) Overlap index
CTV uterus 100.5
Fraction 1 96.9 0.83
Fraction 2 99.8 0.89
Fraction 3 100.3 0.92
Fraction 4 100.4 0.92
Patient 4 D90 (% prescription dose) Overlap index
CTV uterus 103.9
Fraction 1 87.4 0.86
Fraction 2 98.8 0.90
Fraction 3 84.2 0.82
Fraction 4 109.7 0.99
Mean 99.4 0.87
Range 84.2 - 110.0 0.74 - 0.99
The values reflect calculation of radiation doses on megavoltage CT image
guidance scans obtained at the time of treatment, using sample SBRT plans.
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portance for tumor control than percentage coverage by
the prescription dose, so data regarding clinical outcomes
after SBRT are needed before adopting this approach
widely. Our SBRT approach attempts to address this issue,
in part, by including a target volume that receives 48 Gy.
This consideration must be balanced against the poten-
tial advantage of avoiding the risks of anesthesia and the
brachytherapy procedure itself for patients with severe
medical comorbidities.
There are only a limited number of series that report
outcomes after definitive brachytherapy for medically
inoperable endometrial cancer, but the outcomes are gener-
ally good. Coon et al. utilized either a combination of
EBRT and Y-applicator brachytherapy (71%) or Y-applicator
brachytherapy alone (29%) for the treatment of medically
inoperable early stage endometrial cancer and reported 3-
and 5-year actuarial cause-specific survival rates of 93%
and 87%, respectively [4]. Niazi et al. utilized either a com-
bination of EBRT and Y-applicator brachytherapy (21%) or
Y-applicator brachytherapy alone (79%) and found an aver-
age 15-year disease-specific survival rate of 78% for all stages
[9]. Prospective studies of SBRT for medically inoperable
endometrial cancer are warranted to evaluate outcomes
relative to these benchmark data from brachytherapy alone
and in combination with conventionally fractionated EBRT.
Our analysis indicates that acceptable radiation therapy
plans are achievable using this technique, however, this
treatment technique results in high dose distributions
with steep gradients targeting a mobile organ. While inter-
fraction and intrafraction motion is also a consideration in
SBRT for other disease sites, the uterus is unique in that
there is potential for deformation of the target shape due
to variations in bladder and rectal filling. Several studieshave demonstrated significant interfraction motion of the
uterus during definitive EBRT for gynecological tumors
[11,12], raising concerns for the ability to safely deliver
SBRT. However, it is not clear that data regarding uterine
interfraction motion in cervical cancer patients, as in-
cluded in those studies, can be applied to patients with
medically inoperable endometrial cancer, who are often
elderly and may have smaller uteri. Our data indicate that
after daily image guidance with soft tissue alignment,
excellent reproducibility in uterine positioning is achie-
vable. Moreover, when the isodose distributions from the
treatment planning CTs were used to estimate daily dose
delivery to the uterus, the mean D90 for the cohort was
99.4% of the prescription dose. This indicates that despite
small residual errors in uterine positioning, treatment
delivery with this technique results in excellent coverage of
the target volume. An additional consideration for uterine
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which has the theoretical potential to increase the risk of
secondary malignancies. Given the limited life expectancy of
many patients with medically inoperable endometrial cancer,
this is likely not a primary factor for decision-making.
The current study has limitations, most notably the lack
of data regarding clinical outcomes. Prospective clinical
trials of SBRT are needed to develop this approach for im-
plementation. In addition, the brachytherapy treatment
plans used as the comparison in this study include a ma-
jority of cases with single tandem applicator rather than a
Y applicator. Therefore, the CTV coverage provided by
brachytherapy in the current study likely underestimates
what would be achieved with a Y applicator, which is a
preferred treatment approach over single tandem brachy-
therapy [4,5]. The current study was limited to analysis of
brachytherapy alone versus SBRT alone, and did not
address the scenario of pelvic nodal EBRT combined with
brachytherapy or SBRT. It is possible that 2 fractions of
SBRT (8.5 Gy × 2) could be explored as a potential alter-
native to brachytherapy when pelvic EBRT will also be
delivered. This would mimic the addition of 2 fractions of
HDR brachytherapy (8.5 Gy × 2) to 45 Gy of pelvic EBRT,
which is one of the recommended dose schedules in ABS
guidelines [5]. Furthermore, it should be noted that inter-
fraction variation of the uterus was evaluated in a small
number of patients in this study, and additional research
is warranted to assess the significance of organ motion for
patients with medically inoperable endometrial cancer.
We do not recommend that SBRT be pursued for all pa-
tients with medically inoperable endometrial cancer, since
HDR brachytherapy is generally considered to be safe and
effective [4,9], but rather only in those individuals who are
considered to be at unacceptably high risk of complica-
tions from anesthesia, such as the group described by
Kemmerer and colleagues in their evaluation of SBRT as a
boost strategy in lieu of brachytherapy [13]. We would
recommend rigid immobilization for uterine SBRT, as well
as consideration of repeat volumetric imaging during
SBRT if the treatment delivery time is expected to be more
than a few minutes.
Many brachytherapists may be reluctant to contemplate
SBRT as a potential back-up alternative to brachytherapy
for any indication, but it is relevant to consider that pat-
terns of cares studies have shown lower than expected
rates of utilization of brachytherapy for gynecological can-
cers [19], reduced utilization of brachytherapy for elderly
women with cervical cancer [20], and a recent trend
towards decreasing utilization of brachytherapy for
cervical cancer in recent years [21]. Therefore, there
may be value in better exploring and evaluating EBRT-
based approaches as an alternative to brachytherapy
based upon the practical extrapolation of these patterns
of care studies, which would suggest that some patientswith medically inoperable endometrial cancer are likely to
receive treatment without brachytherapy despite the lack
of evidence.
Conclusions
In summary, the SBRT technique evaluated in this study
for medically inoperable uterine cancer seems feasible
with respect to achieving dosimetric objectives, however
concerns remain regarding the effectiveness of SBRT rela-
tive to brachytherapy. With daily image guidance using
soft tissue alignment, adequate coverage of the uterus was
achieved, but this early observation should be evaluated in
a larger cohort. This analysis demonstrated significant
limitations of SBRT, including higher doses to bowel and
rectum than with brachytherapy as well as interfraction
variation in target volume coverage. This treatment
approach appears to be a reasonable potential alternative
to intracavitary HDR brachytherapy for patients with
medically inoperable endometrial cancer at highest risk
of complications from anesthesia and brachytherapy, but
future studies will be needed to evaluate clinical outcomes
after SBRT and the comparative effectiveness relative to
brachytherapy.
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